Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
HealOS›
Analysis
AddedMay 12, 2026
UpdatedMay 30, 2026
HealOS

HealOS

HealOS delivers six AI agents that automate administrative workflows for medical practices.

HQ
Brooklyn, NY, US
Founded
2023
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Contents

  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  4. 04Competitive Risks
  5. 05Pricing Strategy
  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  4. 04Competitive Risks
  5. 05Pricing Strategy

Product Overview

HealOS delivers six specialized AI agents that automate administrative workflows for medical practices. The platform includes AI Scribe for clinical documentation with ICD-10/CPT coding, AI Receptionist for 24/7 call answering and scheduling, Benefits Verification for insurance eligibility, Prior Authorization for automated submissions, Fax and Referrals for document processing, and Billing/RCM for end-to-end revenue cycle management.

The platform integrates with 80+ EHR systems including Epic, Cerner, and Athenahealth via API, Chrome Extension, or HL7/FHIR. HealOS is HIPAA compliant and SOC 2 Type II certified, serving 5,000+ patients across 7 clinics with 12,000+ visits/month handled.

Market Outlook

The healthcare AI automation market is experiencing explosive growth. AI in Revenue Cycle Management is projected to grow from $20.63B (2024) to $70.12B by 2030 (24.16% CAGR). Broader healthcare automation is projected from $46.85B (2025) to $119.19B by 2035 (9.79% CAGR). Key drivers include rising claim denials, acute workforce shortages, the shift to value-based care, and maturation of agentic AI. The 2025-2026 inflection point is characterized by a shift from experimental AI pilots to production-grade end-to-end automation.

North America dominates with 55-60% market share, driven by US healthcare IT infrastructure, outsourcing trends, and regulatory reforms. Asia Pacific is the fastest-growing region (~13.6% growth rate). Key industry moves in 2024-2026 include R1 RCM partnering with Palantir (R37 AI lab), athenahealth launching AI automation, Thoughtful AI launching RCM agents, and RapidClaims securing $11M for AI-driven RCM. CMS interoperability rules now require payers to support electronic prior auth via FHIR APIs, accelerating prior auth automation adoption.

Competitive Advantages

HealOS differentiates through comprehensive workflow coverage with six AI agents handling the complete administrative stack rather than point solutions. The platform achieves 98% accuracy on AI scribe notes and 98% call answer rate with 24/7 availability.

The company secured .2M in funding and demonstrates traction with 5,000+ patients served, 12,000+ visits/month, and 3,200+ hours saved since 2024 deployment. Y Combinator backing provides credibility and access to the YC network. Deep EHR integrations with 80+ systems including Epic create switching costs and distribution advantages.

Competitive Disadvantages

HealOS faces several competitive disadvantages relative to enterprise-focused incumbents: (1) No pre-visit AI charting — cannot aggregate labs, imaging, and consults before visits, unlike DeepScribe; (2) No clinical decision support or undercoding prevention, unlike DeepScribe Assist; (3) Lighter EHR integration depth using Chrome Extension and APIs rather than deep native embedding like Epic SmartData; (4) Lower specialty accuracy (98% general / 95% specialty vs DeepScribe's KLAS-certified 98.8/100); (5) No click-to-source-audio traceability for audit defensibility, unlike Othisis; (6) Narrower target market focused on small-to-mid practices (7 clinics, ~5,000 patients) vs enterprise competitors with deeper deployment histories; (7) Lower pricing ($49-99/mo) creates margin pressure vs competitors charging $400-1,200+/mo; (8) Startup stability risk as a newer, smaller company with limited enterprise track record.

Beyond product-level gaps, HealOS faces structural risks common to AI-first healthcare startups: confusing algorithmic performance with clinical utility, failing at the 'last mile' of clinical integration, and building solutions that are technically impressive but clinically peripheral. High-profile failures like Babylon Health, Olive AI, and IBM Watson Health illustrate these risks. The coding intensity concern shows AI scribes driving up coding intensity, which invites payer pushback — Cigna began auto-downcoding level 4-5 E/M claims in October 2025.

Pricing Strategy

HealOS employs a freemium-to-paid SaaS pricing strategy. The AI Scribe has two tiers: Core at $49/month (unlimited sessions, templates, Chrome extension) and Plus at $99/month (adds EHR sync and direct note transfer). Yearly billing offers a 20% discount. A free tier provides 20 sessions with no credit card required, serving as the acquisition funnel. The AI Receptionist, Fax & Referrals, Benefits Verification, Prior Authorization, and Billing/RCM products use custom pricing requiring a sales conversation, enabling value-based pricing based on practice size and complexity.

This positions HealOS at one-sixth the price of enterprise competitors like DeepScribe ($400-500/mo) and Abridge ($600-1,200/mo), targeting SMB practices priced out of premium offerings. Dedicated onboarding is included at no extra charge, reducing switching costs for new practices.